U.S. Markets close in 2 hrs

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
30.28+0.15 (+0.50%)
As of 1:58PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close30.13
Bid30.10 x 800
Ask30.21 x 1400
Day's Range29.70 - 30.86
52 Week Range15.28 - 40.01
Avg. Volume630,593
Market Cap2.45B
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript
    Motley Fool

    Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript

    Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Dr. Suresh Durgam, Senior Vice President and Chief Medical Officer; and Larry Hineline, Senior Vice President and Chief Financial Officer. As a reminder, during today's call, we will be making certain forward-looking statements.

  • Benzinga

    Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes

    Intra-Cellular Therapies Inc (NASDAQ: ITCI) expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in collaboration with Catalent Inc (NYSE: CTLT), using its proprietary Zydis ODT (orally disintegrating tablet) fast-dissolving formulation. The company completed Phase 1 studies that showed ITI-1284 ODT-SL was rapidly absorbed into the systemic circulation, was metabolically stable, and resulted in high systemic exposure. No serious adverse events were reported. In the elderly cohort, reported adverse events were infrequent, with the most being transient dry mouth (mild). Intra-Cellular plans to develop ITI-1284 ODT-SL to treat behavioral disturbances in patients with dementia-related psychosis and certain depressive disorders in the elderly. Yesterday, the company filed a supplemental marketing application for CAPLYTA (lumateperone) to the FDA for depressive episodes associated with bipolar I or II disorder in adults. Price Action: ITCI shares are up 1.76% at $37.54 on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaIntra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
    Simply Wall St.

    Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...